Abstract:BackgroundTislelizumab, an anti-programmed cell death protein-1 monoclonal antibody, demonstrated clinical activity and was well tolerated in patients with previously treated advanced HCC in the open-label, multicenter, Phase 2 RATIONALE-208 study (NCT03419897). We report exploratory analysis of the association of gene expression profiles (GEPs) with response to tislelizumab in patients with previously treated advanced HCC.MethodsEligible patients who had received ≥1 prior line of systemic therapy for advanced HCC received tislelizumab (200 mg) intravenously once every 3 weeks and tumor response was evaluated per RECIST v.1.1. Baseline tumor sampling was optional and GEP analysis was performed using HTG EdgeSeq Precision Immuno-Oncology panel in 138 tumor samples (fresh tumor, n=6; archival tumor, n=132). Signature scores were calculated using Gene Set Variation Analysis package with publicly available gene signatures (GS). GS or genes differentially expressed between responders and non-responders (NRs) were determined using Wilcoxon rank-sum test and modified t-test with limma. Distributions of overall survival (OS) and progression-free survival (PFS) for GS subgroups (high vs low) were estimated by Kaplan-Meier method. Hierarchical clustering of NRs was achieved using 1-Pearson’s correlation and average linkage. All statistical analysis results are post-hoc exploratory and thereby p values are descriptive.Results249 patients were enrolled and received ≥1 dose of tislelizumab; 138 patients had evaluable GEP data, of which 132 patients had evaluable GEP and tumor response data. GEP analysis demonstrated that CD4 T cell, CD8 T cell, cytotoxic T lymphocyte and major histocompatibility complex class I signatures were enriched in responders, and cancer-associated fibroblasts, angiogenesis and hypoxia signatures were enriched in NRs (figure 1). CD8B_PDCD1_9, a novel GS identified, comprises 9 genes highly expressed in responders: CD8B, CXCL13, KLRD1, NKG7, HLA-A, HLA-G, LAG3, PDCD1 and KREMEN1. Higher objective response rate (ORR; p<0.0001, by Fisher’s exact test) and longer PFS (p=0.005, by log rank test) were observed in patients with high vs low CD8B_PDCD1_9 score (ORR: 26% vs 3%; median PFS: 2.8 months vs 1.8 months). To explore the heterogeneity of molecular features in NRs, NRs were clustered into 3 subgroups using a series of tumor-immune GS. OS and PFS for the 3 NR subgroups with distinct GS are summarized in table 1.Abstact 360 Figure 1Correlation between GS and ORR in patients with previously treated advanced HCC treated with tislelizumab monotherapyAbstact 360 Table 1OS and PFS of NR subgroupsCl, confidence interval; NE, not evaluable; GS, gene signature; NR, non-responder; OS, overall survival; PFS, progression-free survivalConclusionsThis exploratory analysis identified distinct GS associated with tumor response and resistance to tislelizumab monotherapy in patients with previously treated advanced HCC and increases our understanding of the tumor microenvironment. Further GEP analyses will be undertaken in an on-going Phase 3 study (NCT03412773).AcknowledgementsThis study is sponsored by BeiGene Ltd. Medical writing support for the development of this abstract, under direction of the authors, was provided by Claire White, PhD, of Ashfield MedComms, an Ashfield Health company, and was funded by BeiGene Ltd.Trial RegistrationNCT03419897Ethics ApprovalThis study was conducted according to the ethical principles of the Declaration of Helsinki, Good Clinical Practice guidelines, the principles of informed consent and the requirements of the public registration of clinical trials. Written informed consent was obtained from each patient prior to screening. The protocol was approved by the institutional ethics committee and was monitored by a safety monitoring committee.

FP04.02 RATIONALE-307: Updated Biomarker Analysis of Phase 3 Study of Tislelizumab Plus Chemo Vs Chemo Alone for 1L Advanced Sq-NSCLC

P17.02 RATIONALE 307: A Subgroup Analysis of Tislelizumab Plus Chemo Vs Chemo Alone As 1L Treatment for Stage IIIB Advanced Sq NSCLC

137P Tislelizumab Combined with Chemotherapy As Neoadjuvant Therapy for Stage IIIA-IIIB(N2) Potentially Resectable Squamous Non-Small-cell Lung Cancer (TACT)

1263P Tislelizumab + Chemotherapy Vs Chemotherapy Alone As First-Line Treatment for Locally Advanced/metastatic Nonsquamous NSCLC

Perioperative Tislelizumab Plus Neoadjuvant Chemotherapy for Patients with Resectable Non-Small-cell Lung Cancer (RATIONALE-315): an Interim Analysis of a Randomised Clinical Trial

1297P RATIONALE 307: Tislelizumab (TIS) Plus Chemotherapy (chemo) Vs Chemo Alone As First-Line (1L) Treatment for Advanced Squamous Non-Small Cell Lung Cancer (sq NSCLC) in Patients (pts) Who Were Smokers Vs Non-Smokers

Abstract CT552: RATIONALE 304: Tislelizumab (TIS) Plus Chemotherapy Versus Chemotherapy Alone As First-Line (1L) Treatment for Non-Squamous (Non-Sq) NSCLC in Patients (pts) Aged 65-75 Years

Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial

Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial

Tislelizumab Versus Docetaxel in Patients with Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial.

EP08.01-014 Tislelizumab Versus Docetaxel in Previously Treated Advanced Non-Small Cell Lung Cancer: Final Analysis of RATIONALE-303

P2.04-29 Preliminary Results with Tislelizumab in Chinese Patients with Non-Small Cell Lung Cancer (NSCLC)

Phase III study of tislelizumab plus chemotherapy vs chemotherapy alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC).

360 Tumor-immune Signatures Associated with Response or Resistance to Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (HCC)

Effect of Human Hydrosalpinx Fluid on in Vitro Mouse Embryogenesis.

Abstract LB512: RATIONALE-304: The association of tumor mutational burden (TMB) with clinical outcomes of tislelizumab (TIS) + chemotherapy (chemo) versus chemo alone as first-line treatment for advanced non-squamous non-small cell lung cancer (nsq-NSCLC)

OA03.04 Tislelizumab Plus Chemotherapy Vs Chemotherapy Alone As First-line Treatment for Advanced Squamous Non-Small Cell Lung Cancer

LBA57 MHC-II Antigen Presentation Pathway As a Predictive Biomarker for Sintilimab Plus Chemotherapy in First-Line Treatment of Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (Nsq-Nsclc)

86P Efficacy and Safety of IBI110 (Anti-Lag-3 Mab) in Combination with Sintilimab (Anti-Pd-1 Mab) in Advanced Squamous Non-Small Cell Lung Cancer (sqnsclc): Updated Results of the Phase Ib Study

TS01.03 Efficacy and Safety Data from a Phase 1/2 Trial of Tislelizumab in Chinese Patients with Non-Small Cell Lung Cancer (NSCLC)

Phase II trial of safety and efficacy of tislelizumab plus chemotherapy in stage II-IV non small cell lung cancer (LungMark).